share_log

BRIEF-Beigene Provides Update On Phase 2 Clinical Trial Of Zanubrutinib In Patients With Covid-19-Related Pulmonary Distress

Reuters ·  Apr 8, 2021 19:10

April 8 (Reuters) - Beigene Ltd 6160.HK :

* BEIGENE PROVIDES UPDATE ON PHASE 2 CLINICAL TRIAL OF ZANUBRUTINIB IN PATIENTS WITH COVID-19-RELATED PULMONARY DISTRESS

* BEIGENE LTD - TRIAL DID NOT MEET CO-PRIMARY EFFICACY ENDPOINTS; NO NEW SAFETY SIGNALS IDENTIFIED

* BEIGENE LTD - THERE WERE NO NEW OR ADDITIONAL SAFETY SIGNALS FOR ZANUBRUTINIB IDENTIFIED IN TRIAL

Source text for Eikon: Further company coverage:

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment